Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) originally developed through sequence modification of the endogenous peptide tuftsin. Its high structural stability and resistance to enzymatic breakdown make it a frequently studied compound in neuroscience and immunology research models.
In controlled laboratory environments, Selank is widely used to investigate neuropeptide signaling, GABAergic modulation, and monoamine-related biochemical pathways. Preclinical studies also examine how Selank influences gene expression, cytokine activity, and peptide–receptor interactions, making it a valuable tool for analyzing complex regulatory systems in vitro and in vivo (non-human models).
Because of its stability and predictable degradation pathways, Selank serves as a useful research peptide for experiments exploring neurochemical communication, immune signaling crosstalk, and transcriptional regulation.
Primary Research Areas:
- GABAergic receptor modulation and peptide–receptor dynamics
- Monoamine neurotransmitter pathway studies
- Gene expression and transcriptional regulation models
- Cytokine signaling and immune system crosstalk
- Neuropeptide stability and metabolic profiling
- Comparative studies with tuftsin and related peptides
Selank Structure:
Molecular Formula: C33H57N11O49
Molecular Weight: 751.87 g/mol
PubChem ID: 11765600
CAS Number: 129954-34-3
Synonyms: Selanc, TP-7, Tuftsin analog, Heptapeptide Selank, UNII-TS9JR8EP1G
